SOURCE: Medivation, Inc.

Medivation, Inc.

March 01, 2011 08:00 ET

Medivation Announces Participation in Upcoming Conferences

SAN FRANCISCO, CA--(Marketwire - March 1, 2011) - Medivation, Inc. (NASDAQ: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the following conferences:

  • The Cowen and Company 31st Annual Health Care Conference on Tuesday, March 8, at 8 a.m. Eastern Time at The Boston Marriott Copley Place Hotel
  • The Barclays Capital 2011 Global Healthcare Conference on Tuesday, March 15, at 2 p.m. Eastern Time at the Loews Miami Hotel

Dr. Hung will provide an overview of Medivation and its clinical development programs for MDV3100 for prostate cancer and dimebon (latrepirdine) for Alzheimer's and Huntington diseases.
A live audio webcast of each presentation will be available on the "Events and Presentations" page of the "Investor Relations" section of the Company's website at A replay also will be available for 30 days following the live presentation.

About Medivation
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. Together with its corporate partners Pfizer and Astellas, Medivation currently has investigational drugs in Phase 3 development to treat advanced prostate cancer, mild-to-moderate Alzheimer's disease and Huntington disease. For more information, please visit us at

Contact Information

  • Contacts:

    Medivation, Inc.
    Patrick Machado
    Chief Business Officer
    (415) 829-4101

    Nicole Foderaro
    (415) 946-1058